Federal Education Grants

This grant provides funding for researchers and organizations to develop innovative medical countermeasures for treating acute chemical exposures resulting from terrorist attacks or accidental releases, enhancing national preparedness for chemical emergencies.

This grant provides funding for U.S. educational institutions and organizations to support short-term projects that promote less commonly taught foreign languages and area studies through international seminars, curriculum development, or research abroad.

This initiative seeks innovative partnership models from academic institutions to enhance collaboration with the U.S. Army on scientific and technological research, including both open and classified projects.

Grant Title: U.S. Consulate General Hong Kong and Macau, PAS Annual Program Statement - This grant aims to strengthen U.S.-Hong Kong/Macau ties through cultural, academic, and professional exchanges, focusing on areas like STEAM, environmental sustainability, and human rights, while encouraging diversity and collaboration with American experts.

This funding opportunity supports multidisciplinary research and community projects aimed at reducing health disparities related to environmental factors among disadvantaged populations in the U.S.

This funding opportunity provides financial support for small-scale cancer research projects that can be completed quickly, targeting a wide range of organizations, including universities, nonprofits, and businesses, to advance cancer prevention, diagnosis, and treatment.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) aims to support the clinical validation of already analytically validated biomarkers and assays for cancer detection, diagnosis, and treatment monitoring, ensuring they are reliable and ready for use in clinical studies without conducting new trials.

Assay Validation of High Quality Markers for Clinical Studies in Cancer aims to fund the validation of reliable molecular, cellular, or imaging markers for cancer detection, diagnosis, and treatment, ensuring they meet necessary performance standards for use in clinical trials and studies.

The Emerging Global Leader Award (K43 Independent Clinical Trial Required) supports early-career research scientists from low- or middle-income countries in advancing their independent research careers through mentored clinical trials or related studies that address local health priorities.

The Emerging Global Leader Award (K43) supports early-career research scientists from low- or middle-income countries in developing their independent research careers in health-related fields through a mentored experience focused on addressing local health priorities.

Grant Title: Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) aims to support the development and testing of integrated healthcare models that combine HIV/AIDS, Hepatitis, addiction treatment, and primary care services to improve health outcomes for individuals at risk for or living with these conditions.

Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services aims to fund research that develops and tests innovative models of integrated healthcare to improve outcomes for individuals at high risk for or living with HIV, Hepatitis, and substance use disorders by enhancing service delivery and coordination of care.

This grant provides funding to community organizations in the U.S. to develop and implement initiatives that improve health equity for people with disabilities.

This funding opportunity provides up to $1 million to a wide range of organizations to develop a centralized resource for exploring and analyzing single-cell genomics data from the human brain, enhancing research on brain health and disease.

This funding opportunity provides financial support to local and state educational agencies to develop innovative STEM programs focused on transportation, particularly aimed at encouraging underrepresented students, including females and minorities, to pursue careers in this field.

This program provides financial support to graduate institutions in certain U.S. jurisdictions to help recruit and fund talented STEM students who received Honorable Mentions from the NSF Graduate Research Fellowship Program.

This funding opportunity provides financial support to the American College of Radiology to establish a center that will enhance radiotherapy and imaging services for clinical trials in cancer research across the National Clinical Trials Network.

The "Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network" grant is a $3.8 million funding opportunity from the National Institutes of Health, specifically for Queen’s University at Kingston, to support its collaboration with the U.S. in conducting large-scale, multi-site clinical trials for innovative cancer treatments, while ensuring regulatory compliance and efficient data management.

The "NCI National Clinical Trials Network - Network Lead Academic Participating Sites" grant is a funding opportunity from the National Cancer Institute for academic centers to provide scientific leadership and patient recruitment for large-scale, multi-institutional cancer clinical trials, with a focus on treatment trials, rare cancers, and underserved populations, offering up to $1.7 million per year for a six-year project period.